NCT02066103

Broncho-Adventitial Delivery of Paclitaxel to Extend Airway Patency in Malignant Airway Obstruction Patients

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Mercator MedSystems, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Assess the safety and feasibility of local oncological drug delivery into the bronchial wall after recanalization of subjects with malignant airway obstruction. Safety and feasibility (technical success) will be assessed. This localized delivery is intended as an adjunct therapy and all subjects will receive standard of care oncology therapy as determined by their treating physicians.

Conditions

• Malignant Airway Obstruction Secondary to Non-small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Paclitaxel

Timeline

• Start date: 2014-07-01
• Primary completion: 2016-06-01
• Completion: 2016-06-01
• First posted: 2014-02-19
• Last updated: 2018-04-20

Locations

3 sites across 1 country: United States